Natera agreed to acquire Foresight Diagnostics to integrate its PhaseED‑seq phased‑variant enrichment tech, aiming to boost Signatera’s sensitivity and to expand into hematologic MRD testing. Natera said the $275 million deal (with additional earnouts) will accelerate its push into lymphoma MRD and improve ctDNA detection capabilities. Separately, Paradigm Health acquired Flatiron Health’s clinical research business and raised $78 million to scale a community‑based oncology trials network. The deal combined Paradigm’s AI trial infrastructure with Flatiron’s oncology footprint to broaden trial access in community settings and integrate AI into trial management workflows.